Detection of circulating tumor DNA in patients with osteosarcoma

David M. Barris, Shoshana B. Weiner, Robert A. Dubin, Michael Fremed, Xusheng Zhang, Sajida Piperdi, Wendong Zhang, Shahina B. Maqbool, Jonathan Gill, Michael Roth, Bang H. Hoang, David S. Geller, Richard Gorlick, Daniel A. Weiser

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Identification and quantification of somatic alterations in plasma-derived, circulating tumor DNA (ctDNA) is gaining traction as a non-invasive and cost effective method of disease monitoring in cancer patients, particularly to evaluate response to treatment and monitor for disease recurrence. To our knowledge, genetic analysis of ctDNA in osteosarcoma has not yet been studied. To determine whether somatic alterations can be detected in ctDNA and perhaps applied to patient management in this disease, we collected germline, tumor, and serial plasma samples from pediatric, adolescent, and young adult patients with osteosarcoma and used targeted Next Generation Sequencing (NGS) to identify somatic single nucleotide variants (SNV), insertions and deletions (INDELS), and structural variants (SV) in 7 genes commonly mutated in osteosarcoma. We demonstrate that patient-specific somatic alterations identified through comparison of tumor-germline pairs can be detected and quantified in cell-free DNA of osteosarcoma patients.

Original languageEnglish (US)
Pages (from-to)12695-12704
Number of pages10
JournalOncotarget
Volume9
Issue number16
DOIs
Publication statusPublished - Jan 1 2018

    Fingerprint

Keywords

  • Circulating tumor DNA
  • Next Generation Sequencing
  • Osteosarcoma
  • Targeted sequencing
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this